Form 4: Revolution Medicines CEO, Mark Goldsmith, Reports Acquisition of Stock Options and Shares
SEC Form 4 Filing
Mark Goldsmith, CEO of Revolution Medicines, reports the acquisition of 90,000 common stock shares and 314,000 stock options, alongside adjustments to existing holdings.
Summary
- On March 1, 2024, Mark A. Goldsmith, the President and CEO of Revolution Medicines, reported changes in his beneficial ownership of the company's securities.
- Goldsmith acquired 90,000 shares of common stock at $0 and 314,000 stock options with an exercise price of $29.80.
- He directly owns 466,167 shares of common stock.
- He indirectly owns 35,424 shares through the Jonathan Henry Goldsmith Trust, 35,424 shares through the Rebecca Eve Goldsmith Trust, and 327,547 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
- The stock options vest monthly from March 1, 2024, over four years.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares and options by the CEO could be interpreted as a positive sign, but it's not explicitly stated as such.
Positives
- The acquisition of stock options and shares by the CEO could be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The stock options vest monthly from March 1, 2024, over four years, contingent on continued service.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
- The vesting schedule of the options (monthly over four years) is a typical arrangement to incentivize long-term commitment.
Stakeholder Impact
- The reported transactions may influence investor sentiment regarding the company's prospects.
- The vesting of stock options incentivizes the CEO to drive long-term value for shareholders.
Key Dates
| Date | Description |
|---|---|
| December 15, 2011 | Date of the Goldsmith Children's 2011 Irrevocable Education Trust. |
| March 1, 2024 | Date of transaction for common stock acquisition and stock option grant; Vesting Commencement Date for stock options. |
| March 5, 2024 | Date of filing. |
| February 28, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.